Literature DB >> 34014274

Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019-2020: A Test-Negative Study.

Carlos G Grijalva1, Leora R Feldstein2, H Keipp Talbot1, Michael Aboodi3, Adrienne H Baughman1, Samuel M Brown4, Jonathan D Casey1, Heidi L Erickson5, Matthew C Exline6, D Clark Files7, Kevin W Gibbs7, Adit A Ginde8, Michelle N Gong3, Natasha Halasa1, Akram Khan9, Christopher J Lindsell1, Samuel K Nwosu1, Ithan D Peltan4, Matthew E Prekker5, Todd W Rice1, Nathan I Shapiro10, Jay S Steingrub11, William B Stubblefield1, Mark W Tenforde2, Manish M Patel2, Wesley H Self1.   

Abstract

BACKGROUND: Influenza vaccine effectiveness (VE) against a spectrum of severe disease, including critical illness and death, remains poorly characterized.
METHODS: We conducted a test-negative study in an intensive care unit (ICU) network at 10 US hospitals to evaluate VE for preventing influenza-associated severe acute respiratory infection (SARI) during the 2019-2020 season, which was characterized by circulation of drifted A/H1N1 and B-lineage viruses. Cases were adults hospitalized in the ICU and a targeted number outside the ICU (to capture a spectrum of severity) with laboratory-confirmed, influenza-associated SARI. Test-negative controls were frequency-matched based on hospital, timing of admission, and care location (ICU vs non-ICU). Estimates were adjusted for age, comorbidities, and other confounders.
RESULTS: Among 638 patients, the median (interquartile) age was 57 (44-68) years; 286 (44.8%) patients were treated in the ICU and 42 (6.6%) died during hospitalization. Forty-five percent of cases and 61% of controls were vaccinated, which resulted in an overall VE of 32% (95% CI: 2-53%), including 28% (-9% to 52%) against influenza A and 52% (13-74%) against influenza B. VE was higher in adults 18-49 years old (62%; 95% CI: 27-81%) than those aged 50-64 years (20%; -48% to 57%) and ≥65 years old (-3%; 95% CI: -97% to 46%) (P = .0789 for interaction). VE was significantly higher against influenza-associated death (80%; 95% CI: 4-96%) than nonfatal influenza illness.
CONCLUSIONS: During a season with drifted viruses, vaccination reduced severe influenza-associated illness among adults by 32%. VE was high among young adults.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  critical illness; immunization; influenza; vaccination; vaccine effectiveness

Mesh:

Substances:

Year:  2021        PMID: 34014274      PMCID: PMC8682606          DOI: 10.1093/cid/ciab462

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  33 in total

1.  Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).

Authors:  Jill M Ferdinands; Manjusha Gaglani; Emily T Martin; Don Middleton; Arnold S Monto; Kempapura Murthy; Fernanda P Silveira; H Keipp Talbot; Richard Zimmerman; Elif Alyanak; Courtney Strickland; Sarah Spencer; Alicia M Fry
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

2.  Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness.

Authors:  Sheena G Sullivan; Eric J Tchetgen Tchetgen; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2016-09-01       Impact factor: 4.897

3.  Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination.

Authors:  Carlos G Grijalva; Yuwei Zhu; Derek J Williams; Wesley H Self; Krow Ampofo; Andrew T Pavia; Chris R Stockmann; Jonathan McCullers; Sandra R Arnold; Richard G Wunderink; Evan J Anderson; Stephen Lindstrom; Alicia M Fry; Ivo M Foppa; Lyn Finelli; Anna M Bramley; Seema Jain; Marie R Griffin; Kathryn M Edwards
Journal:  JAMA       Date:  2015-10-13       Impact factor: 56.272

4.  Influenza Vaccination Modifies Disease Severity Among Community-dwelling Adults Hospitalized With Influenza.

Authors:  Carmen Arriola; Shikha Garg; Evan J Anderson; Patrician A Ryan; Andrea George; Shelley M Zansky; Nancy Bennett; Arthur Reingold; Marisa Bargsten; Lisa Miller; Kimberly Yousey-Hindes; Lilith Tatham; Susan R Bohm; Ruth Lynfield; Ann Thomas; Mary Lou Lindegren; William Schaffner; Alicia M Fry; Sandra S Chaves
Journal:  Clin Infect Dis       Date:  2017-10-15       Impact factor: 9.079

5.  Multiple imputation using chained equations: Issues and guidance for practice.

Authors:  Ian R White; Patrick Royston; Angela M Wood
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

6.  Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015-2018.

Authors:  Mark W Tenforde; Jessie Chung; Emily R Smith; H Keipp Talbot; Christopher H Trabue; Richard K Zimmerman; Fernanda P Silveira; Manjusha Gaglani; Kempapura Murthy; Arnold S Monto; Emily T Martin; Huong Q McLean; Edward A Belongia; Lisa A Jackson; Michael L Jackson; Jill M Ferdinands; Brendan Flannery; Manish M Patel
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 20.999

7.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season.

Authors:  Lisa A Grohskopf; Elif Alyanak; Karen R Broder; Emmanuel B Walter; Alicia M Fry; Daniel B Jernigan
Journal:  MMWR Recomm Rep       Date:  2019-08-23

8.  Power for tests of interaction: effect of raising the Type I error rate.

Authors:  Stephen W Marshall
Journal:  Epidemiol Perspect Innov       Date:  2007-06-19

9.  Does raising type 1 error rate improve power to detect interactions in linear regression models? A simulation study.

Authors:  Casey P Durand
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

10.  The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings.

Authors:  Ivo M Foppa; Jill M Ferdinands; Sandra S Chaves; Michael J Haber; Sue B Reynolds; Brendan Flannery; Alicia M Fry
Journal:  Int J Epidemiol       Date:  2016-12-01       Impact factor: 7.196

View more
  5 in total

1.  Influenza vaccine acceptance and hesitancy among adults hospitalized with severe acute respiratory illnesses, United States 2019-2020.

Authors:  Kelsey L Lytle; Sean P Collins; Leora R Feldstein; Adrienne H Baughman; Samuel M Brown; Jonathan D Casey; Heidi L Erickson; Matthew C Exline; D Clark Files; Kevin W Gibbs; Adit A Ginde; Michelle N Gong; Carlos G Grijalva; Akram Khan; Christopher J Lindsell; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay S Steingrub; William B Stubblefield; Mark W Tenforde; Kelsey N Womack; Manish M Patel; Wesley H Self
Journal:  Vaccine       Date:  2021-08-07       Impact factor: 4.169

2.  Rapid whole-blood assay to detect SARS-CoV-2-specific memory T-cell immunity following a single dose of AstraZeneca ChAdOx1-S COVID-19 vaccine.

Authors:  Katie E Lineburg; Michelle A Neller; George R Ambalathingal; Laetitia Le Texier; Jyothy Raju; Srividhya Swaminathan; Lea Lekieffre; Caitlyn Smith; Sweera Rehan; Pauline Crooks; Archana Panikkar; Sriganesh Srihari; Rajiv Khanna; Corey Smith
Journal:  Clin Transl Immunology       Date:  2021-08-12

3.  Association of disease severity and death outcome with vaccination status of admitted COVID-19 patients in delta period of SARS-COV-2 in mixed variety of vaccine background.

Authors:  Javaria Aslam; Muhammad Rauf Ul Hassan; Qindeel Fatima; Hala Bashir Hashmi; Mohammad Y Alshahrani; Ali G Alkhathami; Irrum Aneela
Journal:  Saudi J Biol Sci       Date:  2022-05-31       Impact factor: 4.052

4.  Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness.

Authors:  Meagan Stephenson; Samantha M Olson; Wesley H Self; Adit A Ginde; Nicholas M Mohr; Manjusha Gaglani; Nathan I Shapiro; Kevin W Gibbs; David N Hager; Matthew E Prekker; Michelle N Gong; Jay S Steingrub; Ithan D Peltan; Emily T Martin; Raju Reddy; Laurence W Busse; Abhijit Duggal; Jennifer G Wilson; Nida Qadir; Christopher Mallow; Jennie H Kwon; Matthew C Exline; James D Chappell; Adam S Lauring; Adrienne Baughman; Christopher J Lindsell; Kimberly W Hart; Nathaniel M Lewis; Manish M Patel; Mark W Tenforde
Journal:  Influenza Other Respir Viruses       Date:  2022-07-11       Impact factor: 5.606

5.  Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States.

Authors:  Jennifer R Verani; Wesley H Self; Mark W Tenforde; Manish M Patel; Adit A Ginde; David J Douin; H Keipp Talbot; Jonathan D Casey; Nicholas M Mohr; Anne Zepeski; Manjusha Gaglani; Tresa McNeal; Shekhar Ghamande; Nathan I Shapiro; Kevin W Gibbs; D Clark Files; David N Hager; Arber Shehu; Matthew E Prekker; Heidi L Erickson; Matthew C Exline; Michelle N Gong; Amira Mohamed; Daniel J Henning; Jay S Steingrub; Ithan D Peltan; Samuel M Brown; Emily T Martin; Arnold S Monto; Akram Khan; C Terri Hough; Laurence Busse; Caitlin C Ten Lohuis; Abhijit Duggal; Jennifer G Wilson; Alexandra June Gordon; Nida Qadir; Steven Y Chang; Christopher Mallow; Hayley B Gershengorn; Hilary M Babcock; Jennie H Kwon; Natasha Halasa; James D Chappell; Adam S Lauring; Carlos G Grijalva; Todd W Rice; Ian D Jones; William B Stubblefield; Adrienne Baughman; Kelsey N Womack; Christopher J Lindsell; Kimberly W Hart; Yuwei Zhu; Samantha M Olson; Meagan Stephenson; Stephanie J Schrag; Miwako Kobayashi
Journal:  medRxiv       Date:  2021-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.